Reed Friend, MD

Articles by Reed Friend, MD

A panel of 4 experts on multiple myeloma seated at a long table

Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 18th 2023

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

Patient Profile 3: A 68-Year-Old With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 18th 2023

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 11th 2023

Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.

Patient Profile 1: A 70-Year-Old With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 11th 2023

The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.

RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 4th 2023

An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.

Talquetamab for Patients With Relapsed/Refractory MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 4th 2023

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

Bispecific Antibodies: Teclistamab for Patients With Relapsed/Refractory MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 27th 2023

Specialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.

MM: Influence of CAR T-Cell Therapy on Clinical Care

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 27th 2023

The panel discusses how the emergence of CAR T-cell therapy has changed clinical care for patients with multiple myeloma.

CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 20th 2023

A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.

Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 20th 2023

A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.

Assessing Frailty in Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 13th 2023

Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.

Treatment Strategies for Patients With Transplant-Ineligible MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 13th 2023

Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.

Transplant and Treatment Decision-Making in Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 6th 2023

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.

Multiple Myeloma: Data on Outcomes Based On Cytogenetics

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 6th 2023

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.